A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator ' s Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma

Conditions: Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Interventions: Drug: irinotecan; Drug: IBI343; Drug: paclitaxel Sponsors: Innovent Biologics (Suzhou) Co. Ltd. Not yet recruiting

https://clinicaltrials.gov/study/NCT06238843

Source: ClinicalTrials.gov - February 2, 2024 Category: Research Source Type: clinical trials